Dave Kappos Participates in Stanford University’s Rock Center for Corporate Governance’s Lawyering in the Age of AI Series
February 25, 2026
On February 24, 2026, Cravath partner David J. Kappos participated in Stanford University’s Rock Center for Corporate Governance’s “Lawyering in the Age of AI Series: Boardroom Playbook for AI” in Palo Alto, California. The session examined how legal risk and competitive advantage are increasingly being shaped in the boardroom as AI becomes embedded across products, operations and decision‑making. Dave offered insights into how lawyers are advising companies and boards on navigating AI‑related crises and capitalizing on AI‑enabled opportunities.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
February 02, 2026
Hain Celestial Group’s Sale of North American Snacks Business to Snackruptors Inc.
On February 2, 2026, Hain Celestial Group, a leading global health and wellness company, announced that it has reached a definitive agreement to sell its North American Snacks business, including Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks, to Snackruptors Inc., a Canadian, family‑owned snacks manufacturer, for $115 million in cash. Cravath is representing Hain Celestial Group in connection with the transaction.
Deals & Cases
January 27, 2026
Siegfried’s Acquisition of Noramco, Purisys and Extractas
On January 27, 2026, Siegfried, a leading global Contract Development and Manufacturing Organization for the pharmaceutical industry, announced it has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience (“Extractas”). The acquired businesses include Noramco, Purisys and Extractas, three high-quality small molecules drug substances sites. Cravath is representing Siegfried in connection with the transaction.
Deals & Cases
January 08, 2026
Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
Deals & Cases
December 22, 2025
CWAN’s $8.4 Billion Acquisition by Permira and Warburg Pincus
On December 21, 2025, Clearwater Analytics (“CWAN”) announced that it has entered into a definitive agreement to be acquired in a transaction valued at approximately $8.4 billion by a Permira and Warburg Pincus‑led Investor Group (the “Investor Group”), with participation from Temasek. The Investor Group has key support from Francisco Partners. The Special Committee of the CWAN Board of Directors unanimously recommended this transaction and the CWAN Board of Directors subsequently approved this transaction. Under the terms of the agreement, CWAN stockholders will receive $24.55 per share in cash upon completion of the proposed transaction. Cravath is representing the Special Committee of the CWAN Board of Directors in connection with the transaction.
